JP2009502830A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009502830A5 JP2009502830A5 JP2008523189A JP2008523189A JP2009502830A5 JP 2009502830 A5 JP2009502830 A5 JP 2009502830A5 JP 2008523189 A JP2008523189 A JP 2008523189A JP 2008523189 A JP2008523189 A JP 2008523189A JP 2009502830 A5 JP2009502830 A5 JP 2009502830A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylene
- halogen
- aryl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 133
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 56
- 125000000623 heterocyclic group Chemical group 0.000 claims description 55
- 229910052736 halogen Inorganic materials 0.000 claims description 40
- 150000002367 halogens Chemical class 0.000 claims description 40
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims description 27
- 125000002947 alkylene group Chemical group 0.000 claims description 19
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 7
- -1 R ′ Chemical group 0.000 claims description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 54
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 10
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 102000000568 rho-Associated Kinases Human genes 0.000 claims 2
- 108010041788 rho-Associated Kinases Proteins 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 206010017964 Gastrointestinal infection Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 102000011131 Myosin-Light-Chain Phosphatase Human genes 0.000 claims 1
- 108010037801 Myosin-Light-Chain Phosphatase Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010030043 Ocular hypertension Diseases 0.000 claims 1
- 206010053159 Organ failure Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 208000023589 ischemic disease Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000008816 organ damage Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 0 CC(C)IC(CCC(C1)N(*)*)CC1(C)*(C)(C)C Chemical compound CC(C)IC(CCC(C1)N(*)*)CC1(C)*(C)(C)C 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 2
- VZBNAIGAEFJEEX-WGSAOQKQSA-N CC(C)CN(CC(C)C)[C@H](CC1)CC[C@@H]1Oc(c(Cl)c1)cc(C=CN2)c1C2=O Chemical compound CC(C)CN(CC(C)C)[C@H](CC1)CC[C@@H]1Oc(c(Cl)c1)cc(C=CN2)c1C2=O VZBNAIGAEFJEEX-WGSAOQKQSA-N 0.000 description 1
- QYVOLGBZIPOVSS-HDICACEKSA-N CCCCN(CCCC)[C@H](CC1)CC[C@H]1Oc(ccc1c2C=CNC1=O)c2Cl Chemical compound CCCCN(CCCC)[C@H](CC1)CC[C@H]1Oc(ccc1c2C=CNC1=O)c2Cl QYVOLGBZIPOVSS-HDICACEKSA-N 0.000 description 1
- OGNHHNRUWSNYEA-UHFFFAOYSA-N CCCCNC(CC1)CCC1Oc(ccc1c2C=CNC1=O)c2Cl Chemical compound CCCCNC(CC1)CCC1Oc(ccc1c2C=CNC1=O)c2Cl OGNHHNRUWSNYEA-UHFFFAOYSA-N 0.000 description 1
- CYICIBLRDQJLCB-SHTZXODSSA-N CCCCN[C@H](CC1)CC[C@@H]1Oc(c(Cl)c1)cc(C=CN2)c1C2=O Chemical compound CCCCN[C@H](CC1)CC[C@@H]1Oc(c(Cl)c1)cc(C=CN2)c1C2=O CYICIBLRDQJLCB-SHTZXODSSA-N 0.000 description 1
- FOLOFNFIUXAKTG-BETUJISGSA-N CCCN[C@H](CC1)CC[C@H]1Oc(ccc1c2C=CNC1=O)c2Cl Chemical compound CCCN[C@H](CC1)CC[C@H]1Oc(ccc1c2C=CNC1=O)c2Cl FOLOFNFIUXAKTG-BETUJISGSA-N 0.000 description 1
- JOXARZLBTLZPFJ-UHFFFAOYSA-N CCN(CC)C(CC1)CCC1Oc(cc(C=CNC1=O)c1c1)c1Cl Chemical compound CCN(CC)C(CC1)CCC1Oc(cc(C=CNC1=O)c1c1)c1Cl JOXARZLBTLZPFJ-UHFFFAOYSA-N 0.000 description 1
- LIMSIGMDFMYUKA-UHFFFAOYSA-N CCNC(CC1)CCC1Oc(c(Cl)c1)cc(C=CN2)c1C2=O Chemical compound CCNC(CC1)CCC1Oc(c(Cl)c1)cc(C=CN2)c1C2=O LIMSIGMDFMYUKA-UHFFFAOYSA-N 0.000 description 1
- RTHDGXFTVSXYHO-JOCQHMNTSA-N Cc(cc(c(C=CN1)c2)C1=O)c2O[C@H](CC1)CC[C@@H]1N Chemical compound Cc(cc(c(C=CN1)c2)C1=O)c2O[C@H](CC1)CC[C@@H]1N RTHDGXFTVSXYHO-JOCQHMNTSA-N 0.000 description 1
- WLCYOZRJHQABCX-UHFFFAOYSA-N NC(CC1)CCC1Oc(c(Cl)c1C=CN2)ccc1C2=O Chemical compound NC(CC1)CCC1Oc(c(Cl)c1C=CN2)ccc1C2=O WLCYOZRJHQABCX-UHFFFAOYSA-N 0.000 description 1
- KBSJOEJDHQZYQG-UHFFFAOYSA-N N[C@@H](CC1)CC/C1=[O]/c(c(Br)c1)cc(C=CN2)c1C2=O Chemical compound N[C@@H](CC1)CC/C1=[O]/c(c(Br)c1)cc(C=CN2)c1C2=O KBSJOEJDHQZYQG-UHFFFAOYSA-N 0.000 description 1
- SOTIKWJYKQEPQG-HAQNSBGRSA-N N[C@H](CC1)CC[C@@H]1Oc(cc1C=CN2)ccc1C2=O Chemical compound N[C@H](CC1)CC[C@@H]1Oc(cc1C=CN2)ccc1C2=O SOTIKWJYKQEPQG-HAQNSBGRSA-N 0.000 description 1
- XRTZZJKVSCLQQA-PHIMTYICSA-N N[C@H](CC1)CC[C@H]1Oc(cc(C=CNC1=O)c1c1)c1Cl Chemical compound N[C@H](CC1)CC[C@H]1Oc(cc(C=CNC1=O)c1c1)c1Cl XRTZZJKVSCLQQA-PHIMTYICSA-N 0.000 description 1
- CROIMRXJKJJJOR-UHFFFAOYSA-N O=C(c1c2)NC=Cc1cc(OC(CC1)CCC1NCc1cc(cccc3)c3cc1)c2Cl Chemical compound O=C(c1c2)NC=Cc1cc(OC(CC1)CCC1NCc1cc(cccc3)c3cc1)c2Cl CROIMRXJKJJJOR-UHFFFAOYSA-N 0.000 description 1
- RFKHGHPILFCCFX-CALCHBBNSA-N O=C(c1c2)NC=Cc1cc(O[C@H](CC1)CC[C@H]1N(C1CC1)C1CC1)c2Cl Chemical compound O=C(c1c2)NC=Cc1cc(O[C@H](CC1)CC[C@H]1N(C1CC1)C1CC1)c2Cl RFKHGHPILFCCFX-CALCHBBNSA-N 0.000 description 1
- MQHXOTMFMZOJKP-CALCHBBNSA-N O=C(c1c2)NC=Cc1cc(O[C@H](CC1)CC[C@H]1NCc(cc(cc1)Cl)c1Cl)c2Cl Chemical compound O=C(c1c2)NC=Cc1cc(O[C@H](CC1)CC[C@H]1NCc(cc(cc1)Cl)c1Cl)c2Cl MQHXOTMFMZOJKP-CALCHBBNSA-N 0.000 description 1
- GZQYPOITTJUQHS-UHFFFAOYSA-N O=C1NC=Cc(cc2OC(CC3)CCC3N(CC3CC3)CC3CC3)c1cc2Cl Chemical compound O=C1NC=Cc(cc2OC(CC3)CCC3N(CC3CC3)CC3CC3)c1cc2Cl GZQYPOITTJUQHS-UHFFFAOYSA-N 0.000 description 1
- BYLDLMKWKCVHHO-UHFFFAOYSA-N O=C1NC=Cc(cc2OC(CC3)CCC3NCc(ccc(Cl)c3)c3Cl)c1cc2Cl Chemical compound O=C1NC=Cc(cc2OC(CC3)CCC3NCc(ccc(Cl)c3)c3Cl)c1cc2Cl BYLDLMKWKCVHHO-UHFFFAOYSA-N 0.000 description 1
- BWURLRXDQRQBHC-UHFFFAOYSA-N O=C1NC=Cc(cc2OC(CC3)CCC3NCc3cc(Cl)cc(Cl)c3)c1cc2Cl Chemical compound O=C1NC=Cc(cc2OC(CC3)CCC3NCc3cc(Cl)cc(Cl)c3)c1cc2Cl BWURLRXDQRQBHC-UHFFFAOYSA-N 0.000 description 1
- AMGDQHUPGDPSNZ-UHFFFAOYSA-N O=C1NC=Cc(cc2OC(CC3)CCC3NCc3cccc(Cl)c3)c1cc2Cl Chemical compound O=C1NC=Cc(cc2OC(CC3)CCC3NCc3cccc(Cl)c3)c1cc2Cl AMGDQHUPGDPSNZ-UHFFFAOYSA-N 0.000 description 1
- GZQYPOITTJUQHS-WGSAOQKQSA-N O=C1NC=Cc(cc2O[C@H](CC3)CC[C@@H]3N(CC3CC3)CC3CC3)c1cc2Cl Chemical compound O=C1NC=Cc(cc2O[C@H](CC3)CC[C@@H]3N(CC3CC3)CC3CC3)c1cc2Cl GZQYPOITTJUQHS-WGSAOQKQSA-N 0.000 description 1
- QJVVGSVZENUWLR-OKILXGFUSA-N O=C1NC=Cc(cc2O[C@H](CC3)CC[C@H]3NC3CC3)c1cc2Cl Chemical compound O=C1NC=Cc(cc2O[C@H](CC3)CC[C@H]3NC3CC3)c1cc2Cl QJVVGSVZENUWLR-OKILXGFUSA-N 0.000 description 1
- ULRFTORYRITKEX-IYBDPMFKSA-N O=C1NC=Cc2c1ccc(O[C@H](CC1)CC[C@H]1NCC1CC1)c2 Chemical compound O=C1NC=Cc2c1ccc(O[C@H](CC1)CC[C@H]1NCC1CC1)c2 ULRFTORYRITKEX-IYBDPMFKSA-N 0.000 description 1
- RDAQBRIXBUKLRS-OKILXGFUSA-N O=C1NC=Cc2c1ccc(O[C@H](CC1)CC[C@H]1NCC1CC1)c2Cl Chemical compound O=C1NC=Cc2c1ccc(O[C@H](CC1)CC[C@H]1NCC1CC1)c2Cl RDAQBRIXBUKLRS-OKILXGFUSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05016153 | 2005-07-26 | ||
| EP05016153.8 | 2005-07-26 | ||
| PCT/EP2006/007140 WO2007012422A1 (en) | 2005-07-26 | 2006-07-20 | Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009502830A JP2009502830A (ja) | 2009-01-29 |
| JP2009502830A5 true JP2009502830A5 (enExample) | 2009-09-03 |
| JP5049970B2 JP5049970B2 (ja) | 2012-10-17 |
Family
ID=35115842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008523189A Expired - Fee Related JP5049970B2 (ja) | 2005-07-26 | 2006-07-20 | Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体 |
Country Status (36)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2331853T3 (es) | 2005-06-28 | 2010-01-18 | Sanofi-Aventis | Derivados de isoquinolina como inhibidores de rho-cinasa. |
| NZ565668A (en) | 2005-07-26 | 2010-09-30 | Sanofi Aventis | Piperidinyl-substituted isoquinolone derivatives as RHO-kinase inhibitors |
| ES2372067T3 (es) | 2005-07-26 | 2012-01-13 | Sanofi | Derivados de ciclohexilamina isoquinolona como inhibidores de la rho-quinasa. |
| US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
| ATE523493T1 (de) * | 2006-09-11 | 2011-09-15 | Organon Nv | 2-(1-oxo-1h-isochinolin-2-yl) acetamid-derivate |
| HRP20100705T1 (hr) | 2006-12-27 | 2011-01-31 | Sanofi-Aventis | Cikloalkilaminski supstituirani izokinolinski i izokinolinonski derivati |
| CA2673920C (en) * | 2006-12-27 | 2015-03-24 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
| CN101595094B (zh) * | 2006-12-27 | 2013-02-20 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹诺酮衍生物 |
| KR101517154B1 (ko) | 2006-12-27 | 2015-04-30 | 사노피 | Ｒｈｏ-키나제의 억제제로서의 치환된 이소퀴놀린 및 이소퀴놀리논 유도체 |
| RU2009128693A (ru) | 2006-12-27 | 2011-02-10 | Санофи-Авентис (Fr) | Замещенные производные изохинолина и изохинолинона |
| ATE502027T1 (de) | 2006-12-27 | 2011-04-15 | Sanofi Aventis | Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren |
| TW200845988A (en) | 2007-04-05 | 2008-12-01 | Astrazeneca Ab | New compounds and their uses 707 |
| BRPI0818244A2 (pt) * | 2007-10-24 | 2015-06-16 | Merck Sharp & Dohme | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença |
| AU2009262509B2 (en) * | 2008-06-24 | 2014-01-30 | Sanofi | Bi-and polycyclic substituted isoquinoline and isoquinoline derivatives as Rho kinase inhibitors |
| ES2436531T3 (es) | 2008-06-24 | 2014-01-02 | Sanofi | Isoquinolinas e isoquinolinonas sustituidas en posición 6 |
| AU2009262517B2 (en) | 2008-06-24 | 2014-01-09 | Sanofi | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors |
| EP2328871B1 (en) * | 2008-08-25 | 2020-04-01 | Novartis AG | Hedgehog pathway modulators |
| AR073711A1 (es) | 2008-10-01 | 2010-11-24 | Astrazeneca Ab | Derivados de isoquinolina |
| JP6488239B2 (ja) * | 2013-01-18 | 2019-03-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｒｏｃｋ阻害剤としてのフタラジノンおよびイソキノリノン |
| PE20161065A1 (es) | 2013-10-18 | 2016-11-19 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| AU2014338070A1 (en) * | 2013-10-23 | 2016-05-05 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
| FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN105085478B (zh) * | 2014-04-28 | 2019-04-12 | 南京明德新药研发股份有限公司 | 异喹啉磺胺衍生物及其药物组合物和制药用途 |
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| JP6883173B2 (ja) | 2015-05-12 | 2021-06-09 | ヘモストッド エスエー | 改善された血小板産生のための薬理学的特徴およびマイクロ流体特徴の組み合わせ |
| HK1255034A1 (zh) | 2015-07-01 | 2019-08-02 | Crinetics Pharmaceuticals, Inc. | 生长抑素调节剂及其用途 |
| JP2019513804A (ja) | 2016-04-18 | 2019-05-30 | セルジーン クオンティセル リサーチ，インク． | 治療用化合物 |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2019023278A1 (en) | 2017-07-25 | 2019-01-31 | Crinetics Pharmaceuticals, Inc. | MODULATORS OF SOMATOSTATIN AND USES THEREOF |
| ES3028093T3 (en) | 2018-06-07 | 2025-06-18 | Disarm Therapeutics Inc | Inhibitors of sarm1 |
| CN114874236B (zh) * | 2022-06-24 | 2023-05-05 | 中国工程物理研究院化工材料研究所 | 一种五元氮杂稠环骨架及其制备方法 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2485537B2 (fr) | 1977-04-13 | 1986-05-16 | Anvar | Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| WO1992002476A1 (en) | 1990-07-31 | 1992-02-20 | E.I. Du Pont De Nemours And Company | Catalytic equilibration of selected halocarbons |
| US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
| ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| ES2286834T5 (es) | 1996-08-12 | 2011-01-31 | Mitsubishi Tanabe Pharma Corporation | Medicamentos que comprenden un inhibidor de la rho quinasa. |
| JPH1087629A (ja) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | 新規イソキノリン誘導体、およびその医薬用途 |
| AU8872198A (en) | 1997-08-29 | 1999-03-22 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
| TW575567B (en) * | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
| US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
| WO2001053288A1 (en) * | 2000-01-20 | 2001-07-26 | Eisai Co., Ltd. | Novel piperidine compounds and drugs containing the same |
| US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
| US20040171533A1 (en) | 2000-02-29 | 2004-09-02 | Barbara Zehentner | Methods and compositions for regulating adiopocytes |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
| WO2002034712A1 (en) | 2000-10-27 | 2002-05-02 | Takeda Chemical Industries, Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
| WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
| US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
| WO2002100833A1 (en) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
| GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
| WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
| SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
| AU2003281623B8 (en) * | 2002-07-22 | 2009-06-11 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
| KR20050019918A (ko) * | 2002-07-22 | 2005-03-03 | 아사히 가세이 파마 가부시키가이샤 | 5-치환 이소퀴놀린 유도체 |
| CA2502583A1 (en) | 2002-09-12 | 2004-03-25 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinase inhibitory activity and medicament containing the same |
| DE602004019193D1 (de) * | 2003-03-11 | 2009-03-12 | Novartis Ag | Verwendung von isochinolin-derivaten zur behandlung von krebs und erkrankungen im zusammenhang mit map kinase |
| US20040225116A1 (en) | 2003-05-08 | 2004-11-11 | Payne Mark S. | Nucleic acid fragments encoding nitrile hydratase and amidase enzymes from comamonas testosteroni 5-MGAM-4D and recombinant organisms expressing those enzymes useful for the production of amides and acids |
| US20040266755A1 (en) | 2003-05-29 | 2004-12-30 | Schering Aktiengesellschaft | Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine |
| EP1638939A2 (en) | 2003-06-24 | 2006-03-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| WO2005020081A2 (en) | 2003-08-22 | 2005-03-03 | 4Links Limited | Communication system using embedded synchronisation |
| CN1856475A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉钾通道抑制剂 |
| AU2004276236B2 (en) | 2003-09-23 | 2008-01-24 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
| US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
| WO2005035516A1 (ja) | 2003-10-10 | 2005-04-21 | Ono Pharmaceutical Co., Ltd. | 新規縮合複素環化合物およびその用途 |
| US7449477B2 (en) | 2003-11-25 | 2008-11-11 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) |
| WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| WO2005087226A1 (en) | 2004-03-05 | 2005-09-22 | Eisai Co., Ltd. | Cadasil treatment with cholinesterase inhibitors |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| JP4969049B2 (ja) * | 2004-04-06 | 2012-07-04 | 株式会社アマダ | 曲げ加工装置 |
| US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| EP1741525A1 (de) | 2005-07-06 | 2007-01-10 | Trumpf Werkzeugmaschinen GmbH + Co. KG | Vorrichtung zur Aufnahme von plattenförmigen Materialien |
| ES2372067T3 (es) | 2005-07-26 | 2012-01-13 | Sanofi | Derivados de ciclohexilamina isoquinolona como inhibidores de la rho-quinasa. |
| NZ565668A (en) | 2005-07-26 | 2010-09-30 | Sanofi Aventis | Piperidinyl-substituted isoquinolone derivatives as RHO-kinase inhibitors |
| TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
| JP4033221B2 (ja) | 2005-12-02 | 2008-01-16 | ダイキン工業株式会社 | 冷媒加熱装置 |
| TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
| US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
| US7893088B2 (en) * | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
| ATE502027T1 (de) | 2006-12-27 | 2011-04-15 | Sanofi Aventis | Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren |
| HRP20100705T1 (hr) | 2006-12-27 | 2011-01-31 | Sanofi-Aventis | Cikloalkilaminski supstituirani izokinolinski i izokinolinonski derivati |
-
2006
- 2006-07-20 ES ES06776307T patent/ES2372067T3/es active Active
- 2006-07-20 MX MX2008000956A patent/MX2008000956A/es active IP Right Grant
- 2006-07-20 AU AU2006274246A patent/AU2006274246B2/en not_active Ceased
- 2006-07-20 CN CN2006800271401A patent/CN101228132B/zh not_active Expired - Fee Related
- 2006-07-20 NI NI200800024A patent/NI200800024A/es unknown
- 2006-07-20 PL PL06776307T patent/PL1912949T3/pl unknown
- 2006-07-20 EP EP06776307A patent/EP1912949B1/en active Active
- 2006-07-20 RU RU2008106926/04A patent/RU2440988C2/ru not_active IP Right Cessation
- 2006-07-20 DK DK06776307.8T patent/DK1912949T3/da active
- 2006-07-20 RS RS20110494A patent/RS52241B/sr unknown
- 2006-07-20 WO PCT/EP2006/007140 patent/WO2007012422A1/en not_active Ceased
- 2006-07-20 SI SI200631175T patent/SI1912949T1/sl unknown
- 2006-07-20 JP JP2008523189A patent/JP5049970B2/ja not_active Expired - Fee Related
- 2006-07-20 HR HR20110839T patent/HRP20110839T1/hr unknown
- 2006-07-20 NZ NZ565669A patent/NZ565669A/en not_active IP Right Cessation
- 2006-07-20 AT AT06776307T patent/ATE521595T1/de active
- 2006-07-20 CA CA2615663A patent/CA2615663C/en not_active Expired - Fee Related
- 2006-07-20 PT PT06776307T patent/PT1912949E/pt unknown
- 2006-07-20 KR KR1020087002147A patent/KR101336678B1/ko not_active Expired - Fee Related
- 2006-07-20 BR BRPI0614063-7A patent/BRPI0614063A2/pt active Search and Examination
- 2006-07-24 MY MYPI20063516A patent/MY146644A/en unknown
- 2006-07-24 TW TW095126883A patent/TWI412521B/zh not_active IP Right Cessation
- 2006-07-24 GT GT200600327A patent/GT200600327A/es unknown
- 2006-07-25 DO DO2006000177A patent/DOP2006000177A/es unknown
- 2006-07-25 AR ARP060103200A patent/AR057082A1/es unknown
- 2006-07-25 PE PE2006000895A patent/PE20070181A1/es not_active Application Discontinuation
-
2007
- 2007-12-18 ZA ZA200710952A patent/ZA200710952B/xx unknown
- 2007-12-18 CR CR9604A patent/CR9604A/es not_active Application Discontinuation
-
2008
- 2008-01-21 MA MA30586A patent/MA29639B1/fr unknown
- 2008-01-22 IL IL188949A patent/IL188949A/en not_active IP Right Cessation
- 2008-01-25 EC EC2008008136A patent/ECSP088136A/es unknown
- 2008-01-25 TN TNP2008000038A patent/TNSN08038A1/en unknown
- 2008-01-25 US US12/019,799 patent/US8609691B2/en not_active Expired - Fee Related
- 2008-01-28 HN HN2008000130A patent/HN2008000130A/es unknown
- 2008-02-22 NO NO20080965A patent/NO20080965L/no not_active Application Discontinuation
-
2011
- 2011-06-15 US US13/161,003 patent/US8796458B2/en not_active Expired - Fee Related
- 2011-11-24 CY CY20111101153T patent/CY1112085T1/el unknown